In her new role, Kelley will lead the company’s commercial strategy, business development operations, client engagement initiatives, and long-term growth planning as GBI continues expanding its capabilities and market presence.
Kelley brings more than 25 years of experience in the biotechnology and biopharmaceutical industry, with expertise in driving commercial growth, building strategic partnerships, and scaling customer-focused sales organizations across large molecule development and manufacturing services. Before joining GBI, she held senior commercial development roles at KBI Biopharma, Pfanstiehl, and SAFC.
“GBI Biomanufacturing is entering an exciting new phase of growth and capability expansion,” said Jesse McCool, President of GBI Biomanufacturing. “Chandra brings the client and market insights needed to deepen the way we support our early-stage antibody and ADC projects. Her experience structuring integrated and phase-appropriate work packages for rapid early phase supply aligns exceptionally well with GBI’s latest solutions in the mAb and bioconjugation space.”
As Chief Business Officer, Kelley will focus on expanding GBI’s customer base, strengthening strategic partnerships, improving proposal and project evaluation processes, and aligning commercial execution with operational capabilities to support sustainable growth.
“I’m excited to join GBI at such a dynamic stage of growth,” said Kelley. “GBI recently built an impressive expansion in South Florida that adds commercial-scale production capacity for complex biologics, complementing the company’s long-standing expertise in mammalian-based production of recombinant proteins. What stands out most is the organization’s commitment to scientific excellence, operational flexibility, and their unmatched customer service. I look forward to partnering with the team to further strengthen GBI’s position as a trusted CDMO partner supporting clients from development through commercialization.”
GBI has more than 30 years of operating experience in South Florida and supports biologic modalities including protein biologics, bioconjugates, exosomes, and stem cell therapies through an integrated cGMP and regulatory framework. The company also provides GMP manufacturing support across multiple single-use bioreactor scales and integrated drug product manufacturing solutions.
Also read: Viksit Workforce for a Viksit Bharat
Do Follow: The Mainstream LinkedIn | The Mainstream Facebook | The Mainstream Youtube | The Mainstream Twitter
About us:
The Mainstream is a premier platform delivering the latest updates and informed perspectives across the technology business and cyber landscape. Built on research-driven, thought leadership and original intellectual property, The Mainstream also curates summits & conferences that convene decision makers to explore how technology reshapes industries and leadership. With a growing presence in India and globally across the Middle East, Africa, ASEAN, the USA, the UK and Australia, The Mainstream carries a vision to bring the latest happenings and insights to 8.2 billion people and to place technology at the centre of conversation for leaders navigating the future.